The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Author(s): Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
Issue: Mar/Apr 2020 - Volume 24, Number 2
View All Articles in Issue
Page(s): 140-147
Download in electronic PDF format for $75
Abstract: In New Zealand, there are no liquid formulations of omeprazole commercially available, therefore suspensions must be extemporaneously compounded from solid dosage forms for patients with swallowing difficulties. The funding for solid dosage forms of omeprazole changes frequently, often every one to two years, without consideration of the impact this may have when extemporaneously compounded liquid dosage forms are required. This study examined suspensions compounded from various solid dosage forms of omeprazole with the purpose of identifying suitable quality formulations and evaluating their chemical and physical stability. Six different solid dosage forms of omeprazole that are available in New Zealand, including capsules, tablets, and powder, were used to prepare 2-mg/mL suspensions in 8.4% w/v sodium bicarbonate solution. The suspensions were then assessed visually for quality and by quantifying sedimentation rate over 120 minutes. Two products, stored in amber bottles at either 4°C or 25°C, demonstrated acceptable quality over a 30-day period whilst monitoring physical and chemical stability on day 0, 7, 14, 20, and 30. Four of the formulated suspensions were deemed to be of poor quality due to either a lack of uniformity or rapid sedimentation, attributes that could lead to inaccurate dosing. Acceptable quality suspensions were prepared from Losec and Dr. Reddy’s brands of omeprazole 20-mg capsules. For both brands, a change in color was observed after 20 days and 7 days when stored at 4°C and 25°C, respectively. Chemical stability was determined using a stability-indicating high-performance liquid chromatographic method, with >90% of the active remaining for 30 days when kept at 4°C, and 20 days when stored at 25°C. Not all brands are suitable for extemporaneously compounding omeprazole suspensions. Losec and Dr. Reddy’s brands of capsules were suitable to prepare quality omeprazole suspensions. Omeprazole suspensions compounded from these products are stable for 20 days if stored at 4°C and protected from light.
Related Keywords:
New Zealand, omeprazole, proton pump inhibitor, gastroesophageal reflux disease, GERD, gastric ulcer, liquid suspensions, solid dosage forms, proprietary formulations, physical stability, chemical stability
Related Categories:
GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
|
Mar/Apr 2020
Pg. 140-147
|
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Corsini Lindsay, Williams LaVonn A
|
Mar/Apr 2011
Pg. 124-128
|
Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 58
|
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid
Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
|
Nov/Dec 2017
Pg. 500-512
|
Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Spennacchio Antonio, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
|
May/Jun 2023
Pg. 250-255
|
Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid
Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
|
Nov/Dec 2019
Pg. 504-510
|
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
|
Mar/Apr 2012
Pg. 164-166
|
Omeprazole 2-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2006
Pg. 389
|
Omeprazole 2 mg/mL in SyrSpend SF Alka (Reconstituted)
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 409
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
|
May/Jun 2009
Pg. 250-253
|
Lansoprazole 3-mg/mL Oral Suspension
Allen Loyd V Jr
|
May/Jun 2010
Pg. 246
|
Quality Control Analytical Methods: Considerations in Compounding Peroral Solid Dosage Forms
Vu Nicole
|
Mar/Apr 2007
Pg. 145-148
|
Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms
Akers Michael J
|
Jan/Feb 2017
Pg. 47-56
|
Unit Dose Packaging and Repackaging of Solid and Liquid Dosage Forms in an Institutional Setting
McElhiney Linda F
|
Jan/Feb 2010
Pg. 32-38
|
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder
Gupta Vishnu D
|
Sep/Oct 2003
Pg. 386-388
|
Stability of Allopurinol Suspension Compounded from Tablets
Alexander Kenneth S, Davar Nipun, Parker Gordon A
|
Mar/Apr 1997
Pg. 128-131
|
Case Report: Wound Care of a Diabetic Foot Ulcer
Wynn Tom
|
Jul/Aug 2004
Pg. 265-267
|
Aseptic Compounding in New Zealand and the Use of Still Air Boxes
Gargiulo Derryn, Kairuz Therese Eileen
|
Jul/Aug 2006
Pg. 293-295
|
Formulation Development of Modafinil Sprinkle Dosage Form: Study on the Effect of Food on Dosage
Kumaravelrajan Rajagopal, Karthik B, Venkatasan Suba
|
Nov/Dec 2022
Pg. 516-521
|
Return to Top |